12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Other News

Ambry Genetics, Gene by Gene, Myriad Genetics diagnostic news

Ambry and Gene by Gene each filed an antitrust counterclaim against Myriad in response to the patent infringement case Myriad filed in July in the U.S. District Court for the District of Utah. Myriad alleged that the companies are infringing its breast cancer 1 early onset (BRCA1) and...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >